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Analysis of time-dependent risks for infection, 
rejection, and death after pulmonary 
transplantation 
Infection and rejection remain the greatest threats to the survival of pulmonary allograft recipients. 
Furthermore, a relationship may exist between these events, because the occurrence of one may 
predispose to the other. By using multivariate analysis for repeated events, we analyzed the risk 
factors for bacterial, fungal, and viral infection, grade II or greater acute rejection, and death among 
239 lung transplant recipients who received 250 allografts between January 1988 and September 
1993. A total of 90 deaths, 491 episodes of acute rejection, and 542 infectious episodes occurred 
during a follow-up of 6 to 71 months. The hazard or risk patterns of death, infection, and rejection 
each followed an extremely high risk during the first 100 days after transplantation, a second modest 
risk period at 800 to 1200 days, and a lower constant risk. Infection and graft failure manifested by 
diffuse alveolar damage were the major causes of early death (<100 days), whereas infection and 
chronic rejection were primary causes of later death after pulmonary transplantation. By multiva- 
riate analysis, cytomegalovirus mismatching risk for primary infection was the most significant risk 
factor for death, rejection, and infection. Absence of cytomegalovirus prophylaxis was also a risk 
factor for early and late death and late infection. Survival of recipients who received cytomegalovirus 
prophylaxis was significantly improved. Immunosuppression based on cyclosporine versus FK 506 
was a risk factor for late death and late infection. Graft failure manifested by diffuse alveolar 
damage/adult respiratory distress yndrome was a significant risk for death late after transplanta- 
tion. These data suggest he following: (1) The hazard for death, infection, and rejection after 
pulmonary transplantation appears biphasic; (2) lower survival is associated with ischemia- 
reperfusion lung injury represented by diffuse alveolar damage/adult respiratory distress yndrome; 
(3) cytomegalovirus mismatch, absence of cytomegalovirus prophylaxis, and development of 
cytomegalovirus disease are significant threats for death, rejection, and infection after pulmonary 
transplantation; (4) prevention of cytomegalovirus disease should improve survival by decreasing 
the prevalence of infection and rejection. (J THORAC CARDIOVASC SURG 1995;109:49-59) 
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Lung and heart-lung transplantation have become 
acceptable therapeutic alternatives for patients with 
end-stage pulmonary parenchymal or vascular dis- 
eases. 1Nevertheless, urvival at 1 and 2 years after 
lung or heart-lung transplantation remains lower 
compared with kidney, liver, or heart transplanta- 
tion (UNOS Update, January 1994). As a step 
toward improving survival, we retrospectively ana- 
lyzed donor and recipient characteristics, as well as 
events after pulmonary transplantation that influ- 
enced survival and the risk of infection or rejection. 
Patients and methods 
Recipient population. This study examined the experi- 
ence of all 250 lung (99 single lung, 102 bilateral lung, and 
49 heart-lung) recipients who received their allografts at 
the University of Pittsburgh between January 1, 1988, and 
September 30, 1993, and were observed through January 
31, 1994 (Table I). The mean duration of follow-up was 16 
months (range 6 to 71 months). The recipients included 
114 male patients (46%) and 136 female patients (54%) 
whose ages ranged from 1 to 66 years (mean 37 years, 
median 39 years). The diseases that necessitated trans- 
plantation are given in Table I. All but 11 donor and 
recipient pairs were ABO blood type identical (Appendix 
1) but half of the donors and recipients were cytomega- 
lovirus (CMV) mismatched and 56 recipients (22%) were 
at risk of primary CMV infection (donor+/recipient - 
[D+/R-  D (Appendix 2). 
Donor selection. Donor selection criteria included a 
clear chest radiograph, an arterial oxygen tension greater 
than 300 mm Hg at an inspired oxygen fraction of 1.0 with 
a positive end-expiratory pressure of 5 cm H20, no 
evidence of a significant pulmonary contusion, negative 
human immunodeficiency virus antibody and hepatitis 
antigen titers, minimal sputum, and no evidence of aspi- 
ration as detected with a bronchoscope. The causes of 
brain death and other characteristics of the donors are 
listed in Appendix 3. Sixty-eight percent of the donors 
were male and 32 percent were female. Their ages ranged 
from 1 to 55 years (mean 28 years, median 26 years). 
Specimens of blood, urine, and sputum were obtained 
from the donor for smears and cultures. Antibiotic ther- 
apy was started during the transplantation procedure on 
the basis of the results from the sputum Gram stain. 1 
lmmunosuppression. For recipients without pretrans- 
plantation septic lung disease, the immunosuppressive 
therapy consisted of cyclosporine or FK 506 as the pri- 
mary immunosuppressant combined with azathioprine 
and low-dose corticosteroids (10 to 15 rag/day). Immedi- 
ately before transplantation, doses of azathioprine 
(4 mg/kg) and methylprednisolone (500 mg) were admin- 
istered intravenously. Cyclosporine or FK 506 was begun 
by continuous infusion as soon as the recipient was in 
hemodynamically stable condition, which was usually 6 to 
8 hours after transplantation. The cyclosporine dose was 
titrated to maintain a whole blood level of 800 to 1000 
ng/ml by the Abbott TDx method and FK 506 was titrated 
to maintain aplasma level of 1.0 to 1,5 ng/ml. Prophylactic 
Table I. Indications for pulmonary transplantation 
Transplant procedure 
No. SLT BLT HLT 
Pulmonary vascular disease 
PPH 37 6 12 19 
Eisenmenger's syndrome 41 5 16 20 
PH due to other disease 12 6 0 6 
Nonseptic obstructive lung disease 
COPD 52 43 7 2 
al-Antitrypsin deficiency 20 16 4 0 
Septic obstructive lung disease 
Cystic fibrosis 40 0 40 0 
Bronchiectasis 7 0 7 0 
Restrictive lung disease 
Idiopathic pulmonary fibrosis 3 3 0 0 
Sarcoidosis 8 7 0 1 
Others 19 8 10 1 
Retransplantation 11 5 6 0 
Total 250 99 102 49 
PPH, Primary pulmonary hypertension; PH, pulmonary hypertension; 
COPD, chronic obstructive pulmonary disease; SLT, single lung transplan- 
tation; BLT, bilateral lung transplantation; HLT, heart-lung transplanta- 
tion. 
rabbit antithymocyte globulin (1.5 mg/kg per day) for 5 
days was administered only if the recipient remained 
hemodynamically unstable, and cyclosporine or FK 506 
was avoided for 3 to 5 days. The dose of azathioprine was 
titrated to maintain awhite blood cell count of about 5000 
mm 3. For recipients with pretransplantation septic lung 
disease, posttransplantation immunosuppression con- 
sisted only of cyclosporine or FK 506, and their doses were 
titrated to maintain a lower level of immunosuppression 
(cyclosporine 500 to 700 ng/ml, FK 506 0.8 to 1.0 ng/ml). 
Azathioprine and corticosteroids were added to the regi- 
men when a favorable outcome seemed certain or multi- 
ple episodes of grade II acute rejection or greater had 
occurred. 
Antibiotic prophylaxis. The choice of antibiotics and 
duration of treatment were titrated according to the 
results of microbiologic cultures obtained from the donor 
and recipient airways at the time of transplantation and 
periodically thereafter) For recipients without pretrans- 
plantation septic lung disease, clindamycin and ceftazidine 
were begun immediately after transplantation. If the 
recipient and donor airway cultures contained no organ- 
isms, these antibiotics were stopped at 48 to 72 hours. If 
cultures contained oral flora organisms, clindamycin was 
continued for 10 days. If these cultures contained Staph- 
ylococcus organisms, clindamycin was continued and van- 
comycin was added to complete a 10-day course. If these 
cultures contained gram-negative organisms, ceftazidine 
was continued, and another culture-specific antibiotic was 
added to the regimen if Pseudomonas was the gram- 
negative organism isolated. For recipients with pretrans- 
plantation septic lung disease, three or four antibiotics 
active against Pseudomonas aeruginosa or Pseudomonas 
cepacia were begun during the operation and continued 
for 2 full weeks or until the clinical outcome was certain. 
The choice of antibiotics was determined by the antibiotic 
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sensitivities of the organism present in airways of the 
recipient before transplantation. A single-strength ablet 
of trimethoprim ethoxazole was prescribed every other 
day just before the initial hospital discharge. 
Antiviral prophylaxis. Three different regimens of gan- 
ciclovir with or without acyclovir were used in seropositive 
recipients and donors to try to determine the optimal 
regimen that would prevent CMV infection. 3 Although 
these regimens varied in terms of dose and duration of 
treatment, ganciclovir at a dosage of 5 mg/kg twice a day 
from postoperative days 7 to 21 and 5 mg/kg per day from 
postoperative days 22 to 28 was common to all regimens. 
Seronegative recipients and donors received only CMV 
negative blood and blood products. Recipients at primary 
risk of herpes simplex infection (D+/R- )  received acy- 
clovir 400 mg four times a day from postoperative days 7 
to 90. 
Definition and treatment 
Infection. In this analysis, multiple consecutive positive 
microbial cultures from the same body site were consid- 
ered part of the same infectious episode. Clinically impor- 
tant infections at different sites were considered separate 
infectious episodes even if they involved the same organ- 
ism. CMV illness was analyzed separately from other 
bacterial, fungal, and viral infections for risk factor anal- 
ysis. 
CMV illness. CMV infection was defined by the pres- 
ence of CMV in a culture obtained from any body site in 
the absence of symptoms of CMV infection, histologic 
evidence of CMV disease, rejection, or the isolation of any 
other infectious pathogen. CMV disease was defined by a 
positive culture for CMV plus the presence of intracellu- 
lar inclusions typical of CMV in cells or tissue obtained 
from any body site. CMV syndrome was defined by the 
presence of CMV in a culture from any body site plus 
symptoms typical for CMV infection that were not related 
to rejection or isolation of any other infectious pathogens. 
The few (n = 5) episodes of CMV syndrome have been 
included in the group with CMV infection for the purpose 
of this analysis. CMV infection in D+/R-  recipients and 
CMV disease were managed with ganciclovir 5 mg/kg 
twice a day for 2 weeks followed by 5 mg/kg per day for an 
additional week. 
Acute rejection. Acute rejection was defined by histo- 
logic criteria, and only histologically proved episodes of 
acute rejection were tabulated in this analysis. A rejection 
episode was considered resolved when the biopsy speci- 
mens indicated less than grade II acute rejection. Thus 
several consecutive positive biopsy specimens with grade 
II rejection or more were considered only a single episode 
of acute rejection. 
Acute rejection was treated with intravenous methyl- 
prednisolone (1gin/day) for 3 days for the first and usually 
the second episode. Refractory rejection episodes were 
treated with cytolytic therapy of rabbit antithymocyte 
globulin (1.5 mg/kg per day for 5 days) or equine antithy- 
mocyte globulin (10 to 20 mg/kg per day) for 14 days. 
Obliterative bronchiolitis. Obliterative bronchiolitis 
was defined according to histologic 4 or clinical criteria. 5
Clinical criteria included symptoms or cough with or 
without sputum or a decrease in the forced expiratory 
volume in 1 second of 20% or more from baseline that 
Table I I . Possible risk factors for morbidity and 
mortality after transplantation 
A: Donor related 
Age 
Gender 
Cause of brain death 
Arterial blood gases before harvest 
History of smoking 
Culture (blood, urine, sputum) 
Preservation technique 
History of cardiac arrest 
History of respiratory arrest 
History of cardiopulmonary resuscitation 
Requirement for inotropic support 
B: Donor/recipient matches 
ABO blood type 
CMV status 
HLA status 
Gender 
C: Recipient preop, related 
Age 
Gender 
Underlying disease 
Panel reactive antibody 
Year of transplantation 
D: Intraop. related 
Ischemic time 
Type of transplant 
Requirement for cardiopulmonary b pass 
E: Postop. related 
Early and late 
Airway ischemia 
ARDS/DAD 
Rabbit antithymocyte globulin in first week postop. 
CMV prophylaxis 
CMV infection 
CMV disease 
Frequency of acute rejection (->grade II) 
Frequency of infection other than CMV 
Posttransplantation lymphoproliferative disease 
Late 
Obliterative bronchiolitis 
could not be explained by the presence of bronchomala- 
cia, stenosis of the anastomosis, or infection in the al- 
lograft. Obliterative bronchiolitis was treated with the 
same agents as for acute rejection or with Minnesota 
antithymocyte globulin 10 to 15 mg/kg per day for 14 days 
or OKT3 5 mg/day for 10 days. 
Statistical analysis. Data were collected prospectively 
in an ongoing transplant recipient database and were 
analyzed by SAS 6.08. 6 The cumulative survival function 
was estimated by the actuarial (life-table) method and its 
standard error was determined by the Greenwood formu- 
la. 6 Log-rank tests were used to evaluate the differences 
between the survival curves. The Cox proportional hazard 
model was used to identify the independent contribution 
of potential risk factors for infection, acute rejection, and 
death after transplantation. Potential risk factors were 
examined in both the early (postoperative days 0 to 100) 
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Fig. 1. Overall survival after pulmonary transplantation t the University of Pittsburgh (January 1988 to 
September 1993). 
Table III. Causes of early and late death after 
pulmonary transplantation 
Cause No. 
A. Early death (-<100 days) 
Intraoperative bleeding 6 
Technical failure 5 
ARDS/DAD 13 
Infection 25 
Posttransplantation lymphoproliferative disease 1 
Others 3 
Total 53 
B. Late death (>100 days) 
Infection 20 
Obliterative bronchiolitis 8 
ARDS/DAD 2 
Acute rejection 1 
Posttransplantation lymphoproliferative disease 1 
Others 5 
Total 37 
and late phases (postoperative days >100) after pulmo- 
nary transplantation. The variables entered in the risk 
factor analysis forinfection, rejection, and death included 
donor-related factors, donor/recipient matching, recipient 
preoperative and intraoperative related factors, and post- 
operative related factors (Table II: A, B, C, 1), and 
E--early and late). The selection of independent variables 
in the models was a forward stepwise method with a 
critical value for variable inclusion and exclusion of 0.15. 
A p value of 0.05 or less was used to determine the 
significance of variables. 
Results 
Survival. For the overall group of recipients, 
calculated survival was 68% at 12 months and 54% 
at 36 months (Fig. 1). Infection, adult respiratory 
distress yndrome (ARDS)/diffuse alveolar damage 
(DAD), and intraoperative complications (bleeding 
and technical failure)were the major causes of 
death early (0 to 100 days) after transplantation 
(Table III). Infection and obliterative bronchiolitis 
were primary causes of late deaths (> 100 days) after 
pulmonary transplantation (Table III). A hazard 
function analysis for risk of death revealed an 
extremely high risk phase within 100 days after 
transplantation followed by a period of more mod- 
erate risk around 820 days after transplantation 
(Fig. 2). By multivariate analysis, time of transplan- 
tation (before 1992), CMV mismatch for risk of 
primary infection (D+/R-) ,  absence of CMV pro- 
phylaxis, and infection other than CMV were signif- 
icant risk factors for early death after transplanta- 
tion (Table IV). Risk factors associated with later 
death included a panel reactive antibody greater 
than 10%, CMV mismatch (D+,R-) ,  human leu- 
kocyte antigen (HLA-DR) mismatch, absence of 
CMV prophylaxis, CMV disease, DAD/ARDS, and 
cycl sporine-based immunosuppression. Survival of 
the recipients with or without CMV prophylaxis 
(Fig. 3), and FK 506-based versus cyclosporine- 
based immunosuppression (Fig. 4) indicated that 
these factors had independent significant risk for 
death after pulmonary transplantation. 
Acute rejection. Analysis of the risk of acute 
rejection revealed an extremely high risk within the 
first 100 days after transplantation followed by a 
period of intermediate risk around 830 days after 
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Fig. 3. Impact of CMV prophylaxis on survival after pulmonary transplantation.p < 0.05 between the two 
groups by generalized Wilcoxon test. 
transplantation (Fig. 5). By multivariate analysis, 
older donor age (>40 years), CMV mismatch (D+/ 
R - ) ,  CMV disease, single lung transplant proce- 
dure, and pulmonary hypertension were significant 
risk factors for early acute rejection (Table V). Risk 
factors for late acute rejection included previous 
episodes of acute rejection and prior CMV disease 
(Table V). 
Infection. A hazard function analysis for the risk 
of bacterial, fungal, and viral infection including 
CMV revealed an extremely high risk period during 
the first 100 days after transplantation, followed by a 
peak of intermediate risk between 700 and 1300 
days after transplantation (Fig. 6). By multivariate 
analysis, risk factors for infection other than CMV 
early after transplantation ncluded longer donor 
ischemic time (>6 hours), lower donor arterial 
oxygen tension (<350 mm Hg) before harvest, pos- 
itive donor sputum culture, older recipient age (>40 
years), and CMV mismatch (D+/R- )  (Table VI). 
Risk factors for late infection other than CMV 
included older recipient age, CMV mismatch, ab- 
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after pulmonary transplantation. 
sence of CMV prophylaxis, CMV disease, cyclospo- 
rine-based immunosuppression, and previous epi- 
sodes of infection (Table VI). 
Discussion 
This study confirms several important clinical 
impressions that those of us involved in pulmonary 
transplantation have "known" for a long time. 1'7 
First, the risk of infection, rejection, and death is 
greatest in the first 100 days after transplantation 
(see Figs. 2, 5, and 6). Second, death in the first 100 
days is usually due to infection and/or DAD/ARDS 
in the allograft, whereas death more than 100 days 
after transplantation is primarily due to infection 
and obliterative bronchiolitis (see Table III). Fi- 
nally, acute rejection rarely is a cause of death at any 
time after transplantation (see Table III). 
What is new and exciting about this study is the 
analysis of the risk factors for infection, rejection, 
and death. Although some of the risk factors make 
sense (i.e., agree with our clinical impressions), 
some should more strongly reinforce our clinical 
impressions, some do not agree with our clinical 
impressions, and some are conspicuous by their 
absence. 
Not surprisingly, infection other than CMV was a 
significant risk for early death (see Table IV). This 
agrees with our clinical impressions and observa- 
tions (see Table III). Also, not surprisingly, a longer 
ischemic time, lower arterial oxygen tension in the 
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Fig. 6. Hazard rate of infection after pulmonary transplantation. 
donor, positive donor sputum culture, and older 
recipient were significant risk factors for early infec- 
tion. It was distressing to find that a positive donor 
culture, as previously reported 2's and now recon- 
firmed, was still a risk factor for early infection (see 
Table VI). Although our current antibiotic prophy- 
laxis regimen, which is based on Gram stain results 
and modified on the basis of cultures obtained from 
the donor and recipient lungs, has reduced our 
prevalence of early bacterial pneumonia. 9 This is 
apparently not enough because we have not yet 
succeeded in eliminating this risk of infection. 
CMV mismatching (D+/R- )  for risk of primary 
infection, absence of CMV prophylaxis, and the 
development of CMV disease were the most signif- 
icant risk factors for death, rejection, or infection 
both early and late after pulmonary transplantation 
(see Tables IV, V, and VI). Actuarial survival of 
recipients without CMV prophylaxis was signifi- 
cantly lower than that of recipients who received 
prophylaxis (see Fig. 3). This suggests that prophy- 
laxis for CMV can favorably influence the outcome 
of lung transplantation. 3 On the other hand, these 
results uggest that matching by donor and recipient 
CMV status might be advisable ifwe cannot develop 
a regimen that can prevent this infection in this 
high-risk group of recipients. 
Currently, despite our prophylaxis regimen, CMV 
disease develops in 52% (25/48) of our D+/R-  
recipients, but in the vast majority (22/25, 80%) this 
disease has occurred after completion of CMV 
prophylaxis (unpublished ata). Thus our current 
Table IV. Risk factors for death after pulmonary 
transplantation 
Risk factors p Value Risk ratio 
A. Early death 
Demographic 
Year of transplantation 0.01 0.68 
Matching 
CMV mismatch 0.01 1.27 
Clinical 
No CMV prophylaxis 0.0001 0.40 
Infection episode 0.01 270.70 
B. Late death 
Matching 
PRA >10% 0.05 2.37 
CMV mismatch 0.01 1.38 
HLA-DR mismatch 0.01 2.06 
Clinical 
No CMV prophylaxis 0.02 0.64 
CMV disease 0.03 0.82 
DAD/ARDS 0.01 2.37 
Cyclosporine immunosuppression 0.02 0.34 
PRA, Panel reactive antibody. 
CMV prophylaxis appears only to delay the emer- 
gence of CMV disease. The optimum regimen of 
prophylaxis for D+/R-  recipients remains to be 
determined. 
With experience and refinement of operative 
technique, 2 the number of intraoperative complica- 
tions was significantly reduced (January 1988 to 
December 1991, 17%; January 1992 to September 
1993, 4%, p < 0.05) and survival was significantly 
improved. 2 This result is well correlated with the 
fact that year of transplantation was a significant risk 
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Table V. Risk factors for acute rejection after 
pulmonary transplantation 
Risk factors p Value Risk ratio 
A. Early rejection 
Donor 
Older donor 0.03 1.01 
Demographic 
SLT 0.03 0.55 
PH 0.02 0.45 
Matching 
CMV mismatch 0.001 0.54 
Clinical 
CMV disease 0.0001 0.32 
B. Late rejection 
Clinical 
Prior rejection episodes 0.0002 1.33 
CMV disease 0.0001 0.43 
SLT, Single lung transplantation; PH, pulmonary h pertension. 
factor for early death after pulmonary transplanta- 
tion. 
Obliterative bronchiolitis was the second most 
frequent cause of late death and was frequently 
associated with pulmonary graft infection. 1°' 11 A 
recent analysis of risk factors for the development of
obliterative bronchiolitis at our institution indicated 
that CMV disease and frequent, severe acute rejec- 
tion episodes were the primary risk factors for the 
subsequent development of obliterative bronchioli- 
tis. n 
The results from this study further supported the 
early results of our ongoing randomized study com- 
paring FK 506 versus cyclosporine in pulmonary 
transplantation. 12 Even with year of transplantation 
accounted for, this multivariate analysis howed that 
FK 506-based immunosuppression resulted in bet- 
ter survival (see Fig. 4) and less risk for late infec- 
tion (see Table VI). However, the duration of 
follow-up is still limited to a mean of 13 months in 
the FK 506 group and 19 months in the cyclosporine 
group. Also the two groups in this analysis were not 
randomized. 
A panel reactive antibody greater than 10% and 
HLA-DR mismatching were also associated with an 
adverse outcome. The higher panel reactive anti- 
body is probably associated with more aggressive 
acute rejection, which histologically and clinically 
might look like DAD/ARDS. HI_A-DR mismatch- 
ing may affect outcome via its permissive ffect on 
CMV disease, which is most probably why it sur- 
faced as a risk factor for infection other than CMV 
(see Table VI). Development of graft failure mani- 
fested by DAD/ARDS was also associated with an 
Table VI. Risk factors for infection after pulmonary 
transplantation 
Rhk factors p Value R&k ratio 
A. Early infection 
Donor 
Long ischemic time 0.0006 1.46 
Lower arterial oxygen tension 0.01 1.95 
Sputum culture (+) 0.004 0.71 
Demographic 
Older ecipient 0.01 1.02 
Matching 
CMV mismatch 0.006 1.33 
B. Late infection 
Demographic 
Older ecipient 0.02 1.02 
Matching 
CMV mismatch 0.05 1.20 
Clinical 
No CMV prophylaxis 0.0001 0.66 
CMV disease 0.03 1.25 
Cyclosporine immunosuppression 0.02 0.60 
Prior infection episodes 0.007 1.31 
adverse outcome. The reason that DAD/ARDS is a 
significant risk factor for late but not early death is 
unexplained, because the majority of the episodes of 
DAD/ARDS were related to poor graft preservation 
and usually occurred early after transplantation. 9 
The most probable explanation for this observation 
is that most of the recipients with DAD/ARDS 
survived more than 100 days (mean 121 days). The 
majority of the recipients with DAD/ARDS died of 
late infection, which was most likely related to 
prolonged intubation and long stay in the intensive 
care unit. 
Several risk factors identified in this study remain 
unexplained. For example, why should older donors 
(>40 years old), candidates with pulmonary hyper- 
tension, and recipients of single lung transplants 
have a greater isk of acute rejection? In addition, 
several risk factors that should have been present 
were not recognized in this study. For instance, 
acute rejection a d prevalence of obliterative bron- 
chiolitis should be risk factors for infection, but 
these factors were risks for late infection only by 
univariate analysis and they failed to reach statistical 
significance by multivariate analysis. Longer co- 
hort13, 14 and a larger number of recipients including 
a multicenter study 15 may be necessary to defini- 
tively answer these important questions. 
In summary, the risks for death, infection, and 
rejection after pulmonary transplantation appear to 
be biphasic. Lower survival is associated with isch- 
emia-reperfusion lung injury represented by DAD/ 
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ARDS. CMV mismatch, absent CMV prophylaxis, 
and the development of CMV disease were the most 
significant hreats for death, rejection, and infection 
after pulmonary transplantation. Thus adequate 
prevention of CMV disease should improve survival. 
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Discussion 
Dr. Craig R. Smith (New York, N.Y.). This is an 
exhaustive review of a large number of variables and is 
further evidence of Pittsburgh's leadership in this area. I
agree with most of the conclusions, but I do have a few 
comments. 
I noticed that only 6% of your patients had restrictive 
lung disease, which is a far smaller proportion than one 
would expect from the registries. Does this reflect a bias 
on your part against hat diagnosis? If so, which patients 
with restrictive lung disease should receive a transplant? 
Your experience seems to favor double lung transplan- 
tation for pulmonary hypertension. I assume, then, that 
you would list patients with pulmonary hypertension for 
double lung and not single lung transplantation. 
There has been a controversy running through the 
United Network for Organ Sharing (UNOS) about 
whether or not blood group O recipients are disadvan- 
taged by current policy allowing ABO-compatible match- 
ing. It was curious in your experience that only five ABO 
donors of the entire 250 were placed in A or B recipients. 
If there is a disadvantage, it is not obvious in Pittsburgh. Is 
the size of your waiting list the reason for that? 
Finally, what emerges from this series and many others 
is that CMV infection and disease is a persistent and 
serious problem. I am particularly aware of this at the 
moment, as I defend myself in a lawsuit brought against 
me because of a decision to put a CMV-positive heart- 
lung block in a CMV-negative recipient. I think the 
waiting list in the United States is long enough that it 
would always be possible to find a CMV-negative recipi- 
ent for any CMV-negative donor. The "problem" is that it 
may not be my recipient or your recipient. With more than 
70 centers in the United States claiming expertise in lung 
transplantation a d competing for 750 donors, magnani- 
mous gestures are not going to be very frequent, and strict 
CMV matching would probably have to be mandated. Do 
your data support such a mandate, or has prophylaxis 
made this question moot? If you do not think your data 
support a mandate, what level of evidence would it take? 
Would you have to see a clear difference in survival, or 
would a difference in morbidity and cost be enough? 
Dr. Bando. Thank you very much for your comments, 
Dr. Smith. Let me answer your question regarding candi- 
dates with restrictive lung disease. Patients with idiopathic 
pulmonary fibrosis (IPF) constitute the largest group of 
candidates with restrictive lung disease. These patients 
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constitute 13% of our referrals, but only 2% of our 
recipients. This is because this group of candidates is 
much more likely to die waiting compared with patients 
with other types of lung disease. In our most recent 
analysis of the patients accepted as candidates between 
1990 and 1993, 47% of the candidates with IPF have 
already died waiting compared with only 7% of the 
candidates with emphysema. 
The second question regarding single versus bilateral 
lung transplantation for pulmonary hypertension is con- 
troversial. Our preference and our results suggest hat 
bilateral lung transplantation for pulmonary hypertension 
is the better procedure because single lung transplant 
recipients have a significant ventilation/perfusion mis- 
match between the allograft and native lung. As a result, 
they appear to have less oxygenation reserve compared 
with bilateral lung transplant recipients when complica- 
tions develop in the allograft. However, because of the 
shortage of donor organs and the results of significant 
(20% in Pittsburgh) risk of death while waiting, we still do 
single lung transplant, because we do not know how long 
that particular candidate needs to wait until we would get 
a good bilateral lung donor. Thus we list candidates with 
pulmonary hypertension for either single or bilateral lung 
transplant, and we perform a transplant with whatever 
donor first becomes available. 
Your third question regards the transplantation of 
organs from blood group O donors into A or B recipients. 
As you pointed out, the small number of such transplants 
in our experience (5/250 = 2%) is probably because of our 
large candidate list. With more than 200 candidates on our 
waiting list all the time, we rarely encounter a situation in 
which we do not have a suitable ABO identical recipient 
for every donor. 
Your fourth question relates to the risk and conse- 
quences of CMV infection/disease in recipients at risk for 
primary CMV illness (R- /D+) .  CMV disease is a signif- 
icant risk factor for acute rejection, other infections, 
chronic rejection, and increased mortality. CMV matching 
would eliminate this problem, but CMV seronegative 
recipients would undoubtedly have to wait longer for a 
seronegative donor to become available and hence have a 
higher risk of death while waiting for a suitable donor. 
Thus we would rather try to find a good prophylac- 
tic regimen for CMV infection than go with CMV match- 
ing. 
Dr. Alee Patterson (St. Louis, Mo.). Dr. Bando has once 
again demonstrated why the Graham Committee made 
such a wise choice several years ago in selecting him as 
a Graham Fellow. He continues to produce a prolific 
amount of work. I would also point out that Dr. Bahnson 
is here in the audience. It must be a proud moment for 
you to see two of your young colleagues presenting two 
great papers in this forum. It is a real tribute to your whole 
program. 
I am a statistical neophyte. However, when an enor- 
mous number of data points are put into a computer and 
30 or 40 risk factors are evaluated, it seems to me that 
chance alone is going to make a couple of them signifi- 
cant. I am particularly interested in the CMV because it is 
a big problem for us. You notice an identification of CMV 
disease like true infection, biopsy-proved infection, as a 
risk factor. We know also from your own data that CMV 
disease is going to occur whenever the prophylaxis is 
stopped. The onset can be delayed, but the disease is 
going to occur anyway. Does it matter when that CMV 
disease occurs? In other words, is there any difference 
between CMV disease arly on versus CMV disease that 
occurs many months after transplantation? 
Dr. Bando. Thank you for your kind comments, Dr. 
Patterson. In this analysis, we did not separately analyze 
the effect of early versus late onset of CMV as risk factors 
for subsequent events. As you mentioned, CMV disease 
still develops in 65% of recipients at risk for primary 
infection despite up to 90 days of prophylaxis with gancy- 
clovir. Most (96%) of these recipients do develop CMV 
after gancyclovir prophylaxis has been completed. Thus 
our current regimen of CMV prophylaxis for recipients at 
risk of primary illness is not adequate. We have started 
another andomized trial of two different CMV prophy- 
lactic protocols for this CMV R- /D  + group. Dr. Paradis, 
a coauthor of this study, is in charge of this project. He will 
eventually let us know whether early or late onset CMV 
infection make any difference in outcome and whether we 
are able to find more efliciacious prophylactic regimen 
particularly for R - /D+ recipients. 
Dr. Thomas M. Egan (Chapel Hill, N.C.). Dr. Bando, 
how many patients in your analysis had their transplant 
operation before ganciclovir was readily available? Is it 
possible that the impact of CMV disease is less problem- 
atic now than it was in the days before ganciclovir? How 
much has that changed your analysis? 
Dr. Bando. Only 12 recipients in the first 6 months of 
1988 had transplantation without receiving CMV prophy- 
laxis and we did not remove this small number from the 
rest of our group for the purpose of this analysis. Thus we 
do not know whether this might have significant impact on 
our results. Because the number of recipients not receiv- 
ing prophylaxis  so small, however, we doubt that this 
significantly affected our results. 
Dr. Joel D. Cooper (St. Louis, Mo.). I want to address an 
issue of CMV which I think is important. And I would love 
to defend Dr. Craig. We do keep an international registry. 
It is voluntary. We have about 2700 patients in it. One of 
the analyses that we have done is to study the influence of 
CMV. We have looked at the two extreme groups: the 
negative recipient who gets the negative donor, and rarely 
gets CMV infection, and the negative recipient who gets a 
positive donor, and always gets CMV disease. In fact, half 
the world's transplants are not a mismatch. A quarter are 
negative/negative and a quarter are positive donor/nega- 
tive recipient. By analyzing the two extreme groups, both 
in our own series and in the world series as reported to us, 
we find absolutely no difference whatsoever in the 1- or 
2-year survival between the matched and mismatched 
groups. In our own series there is no difference in 
pulmonary function studies at 1 and 2 years. Yes, it is 
costly to use prophylaxis. Yes, the CMV disease occurs in 
the one case and not at all in the other. However, we have 
been unable to detect any difference whatsoever in 1- and 
2-year survivals between the negative recipient groups 
who get either a positive or negative donor. I think one 
need not absolutely restrict negative recipients to negative 
donors. 
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Appendix 1. Matching of donor and recipient ABO 
blood type 
Blood type Patients 
Donor Recipient No. % 
A A 88 35 
O A 4 2 
B B 35 14 
O B 1 <1 
AB AB 6 2 
A AB 4 1 
B AB 2 <1 
O O 110 44 
250 100 
Appendix 2. Matching of donor and recipient CMV 
status before transplantation 
CMV status Patients 
Donor Recipient No. % 
- - 65  26  
- + 77 31 
+ - 56 22 
+ + 52 21 
250 100 
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Appendix 3. Donor characteristics 
Donor 
No. % 
Sex 
Male 
Female 
Cause of death 
Gunshot wound 
Intracranial bleeding 
Motor vehicle accident 
Head trauma 
Others 
Smoking history 
Cardiac arrest 
Respiratory arrest 
Cardiopulmonary resuscitation 
Sputum Gram stain positive for 
gram-negative rods 
Inotropic support >10 mg/kg per minute 
169 
81 
50 
77 
65 
34 
24 
76 
27 
28 
27 
27 
31 
68 
32 
20 
31 
26 
14 
10 
30 
11 
11 
11 
11 
12 
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